Keytruda filing comes early as data shine at the AACR
This article was originally published in Scrip
Executive Summary
Merck & Co crowned a busy day of data presentations at the AACR meeting in Philadelphia on Sunday 19 April with news that it has filed its anti-PD-1 immunotherapy product Keytruda (pembrolizumab) in the US a little earlier than expected in second-line non-small lung cancer.